• Ertugliflozin: Designing Translational SGLT2 Studies

  2026-08-27

  Explore how PF-04971729 supports rigorous diabetes mellitus research by connecting selective renal glucose transport inhibition with cardiovascular, renal, and intestinal endpoints. This guide focuses on evidence calibration and assay design rather than repeating a conventional SGLT2 inhibitor overview.

• Cyclosporin A as a Causal Probe of Mitophagy

  2026-08-26

  Cyclosporin A is more than an immunosuppressive reagent: it can serve as a mechanistic probe for cyclophilin-linked mitochondrial injury and pyroptosis. This article translates recent chondrocyte research into a rigorous assay strategy while defining the compound’s interpretive limits.

• Losartan Research: AT1 Workflows and TME Insights

  2026-08-26

  Use Losartan as a mechanistically focused angiotensin II receptor antagonist for receptor assays, vascular smooth muscle cell proliferation inhibition, and hypertension research. This workflow also shows how a tumor-myeloid phenotypic-screening study can improve assay design without overstating Losartan’s role in cancer biology.

• BPN-19186: A Redox Assay Decision Framework

  2026-08-25

  Explore BPN-19186 as a research tool for connecting soluble epoxide hydrolase, EET metabolism, and Nrf2-ARE signaling. This evidence-aware guide emphasizes assay design, chemical handling, and the distinction between pathway validation and compound-specific proof.

• TH287 Sensitizes CRPC Cells to Ionizing Radiation

  2026-08-25

  A 2026 study identifies TH287-mediated MTH1 inhibition as a radiosensitizing strategy in PC-3 and DU-145 castration-resistant prostate cancer cells, with the strongest combination effect when irradiation followed drug exposure by 12 hours. The work connects oxidized nucleotide stress with apoptosis and cell-cycle disruption while highlighting treatment timing as a key variable for combination experiments.

• L-Glutathione Reduced in Redox Assays

  2026-08-24

  L-Glutathione Reduced gives researchers a practical way to tune thiol-dependent redox conditions, validate oxidative-stress readouts, and elute GST-tagged proteins. This workflow connects redox controls with GOT1-centered pancreatic cancer metabolism while emphasizing fresh preparation, assay-specific controls, and interpretation limits.

• Hoechst 33342/PI Double Staining Kit Guide

  2026-08-23

  The Hoechst 33342/PI Double Staining Kit provides a two-color research workflow for distinguishing cells by nuclear chromatin condensation and membrane integrity. It is intended for fluorescence-based apoptosis and necrosis assays in basic research, not for diagnostic, clinical, or medical use.

• U0126-EtOH: A Translational Lens on MEK1/2

  2026-08-22

  A mechanistic and strategic guide to using U0126-EtOH as a MEK1/2 inhibitor across neuronal, inflammatory, and leukemia research while preserving translational rigor.

• MSNs Deliver Sulforaphane to Suppress NSCLC Metastasis

  2026-08-21

  The reference study identifies an SPI1/miR-616-5p regulatory axis that promotes NSCLC invasion and migration and shows that sulforaphane can inhibit this pathway. Its main translational innovation is an HA- and folic acid-modified mesoporous silica nanoparticle system that improves sulforaphane stability, uptake, tumor targeting, and anti-metastatic activity in xenograft models.

• MST1/2 Control Macrophage Death in Infection

  2026-08-21

  The reference study shows that Hippo kinases MST1/2 act as a convergent apoptotic module in macrophages exposed to sterile inflammatory signals and bacterial pathogens. Its comparative design reveals that macrophages can switch between MST1/2-associated apoptosis and GSDMD-mediated pyroptosis, providing a framework for interpreting DNA fragmentation alongside inflammatory cell-death markers.

• Vorinostat: HDAC Workflows for Cancer Research

  2026-08-20

  Build reproducible epigenetic, viability, and mitochondrial apoptosis workflows with Vorinostat while separating chromatin engagement from the event that actually commits a cell to death. A recent RNA Pol II study adds a practical mechanistic layer: loss of RNA Pol IIA can activate apoptosis independently of transcriptional shutdown.

• SAR131675: VEGFR-3 Inhibitor Workflow

  2026-08-20

  Use SAR131675 to separate VEGFR-3-dependent lymphatic, endothelial, macrophage, and fibrosis phenotypes in mechanism-focused assays. Its nanomolar potency and strong kinase selectivity support clean pathway interrogation, while solubility constraints and discontinued development make formulation control and translational caution essential.

• Tetrandrine: Calcium Signaling for Better Assays

  2026-08-19

  Tetrandrine is a versatile Tetrandrine alkaloid for calcium-channel, inflammation, neuroscience, and cancer biology research. This assay-focused guide explains how to translate its membrane-level activity into reproducible experiments while distinguishing validated ion-channel work from exploratory antiviral hypotheses.

• DDI2–NFE2L1 Protects Cells from Ferroptosis

  2026-08-19

  The reference study identifies DDI2-mediated cleavage of NFE2L1 as an adaptive mechanism that restores proteasome function during ferroptosis. Its findings connect lipid-peroxidation stress, ubiquitin-proteasome system remodeling, and pharmacological DDI2 inhibition, providing a mechanistic framework for ferroptosis-sensitization studies.

• SAR131675: Translating VEGFR-3 Selectivity

  2026-08-18

  SAR131675 is a selective, ATP-competitive VEGFR-3 inhibitor that connects receptor-level pharmacology with lymphangiogenesis, angiogenesis, and tumor biology. This thought-leadership analysis examines its evidence hierarchy, selectivity window, experimental use, translational limitations, and relevance to vascular remodeling research informed by nicotine-associated chronic kidney disease biology.

456 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page